lme() answer and beyond ... [General Sta­tis­tics]

posted by d_labes  – Berlin, Germany, 2010-07-14 12:41 (5815 d 20:00 ago) – Posting: # 5621
Views: 16,984

Dear Helmut!

❝ OK, I end up after 7 iterations at:

-2* REML log(likelihood)      251.724

❝ Same result if use the default convergence criterion (10-10),

❝ yours ((10-8), or approach numeric resolution.


Here the results using R's lme().
Code used:
model2 <- lme(log(Cmax) ~ tmt + period + sequence,
              random=list(subject=pdSymm(form= ~tmt-1)),
              weights=varIdent(form = ~ 1 | tmt),
              data=PKparms, method="REML", na.action=na.omit)
summary(model2)

Answer:
Linear mixed-effects model fit by REML
 Data: PKparms
      AIC     BIC   logLik
  291.654 320.096 -135.827  # -2*LL = 271.654! Seems WNL computes different.

Random effects:
 Formula: ~tmt - 1 | subject
 Structure: General positive-definite
         StdDev   Corr
tmtR     0.574772 tmtR
tmtT     0.705001 0.642
Residual 0.431758           # s2=0.186415

Variance function:
 Structure: Different standard deviations per stratum
 Formula: ~1 | tmt
 Parameter estimates:
       R        T
1.000000 0.993312           # very interesting: variability of T lower then R.

Fixed effects: log(Cmax) ~ tmt + period + sequence
               Value Std.Error DF  t-value p-value
(Intercept)  5.60475 0.1867666 86 30.00937  0.0000
tmtT        -0.14753 0.1153259 86 -1.27927  0.2042
period       0.08578 0.0534769 86  1.60402  0.1124
sequenceRTR  0.17906 0.2209845 41  0.81027  0.4225
sequenceTRR -0.28646 0.2297086 41 -1.24704  0.2195


Ok the random effects parameters can't directly compared, only via th G matrix.

getVarCov(model2)
Random effects variance covariance matrix
        tmtR    tmtT
tmtR 0.33036 0.26032          # SAS: 0.3313  0.2581
tmtT 0.26032 0.49703          #      0.2581  0.3596

intervals(model2,which="var-cov",level=0.95)
Error in intervals.lme(model2, which = "var-cov", level = 0.95) :
  Cannot get confidence intervals on var-cov components: Non-positive
  definite approximate variance-covariance


Seems that the difference in intra-subject variability is absorbed by the G matrix, with no loss in the fit (nearly identical -2*LL).

Quintessence for scABE using the EMA approach:
                                              -- Widened (EMA)
             ----- 90% CIs -----              acceptance range --
           point est.  lower  upper     s2WR    lower   upper
FDA (MoM)   0.8746    0.7216  1.0605  0.14332   0.7500  1.3334
SAS (FDA)   0.8632    0.7037  1.0498  0.1862    0.7204  1.3881
WNL             ?                     0.18616   0.7204  1.3881
lme()       0.8628    0.7123  1.0452  0.18642   0.7203  1.3884


Confusion :cool:: scABE not proven.

Astonishing enough the 95% upper confidence interval of the linearized scABE criterion
TR)2-theta2*sigma2WR = -0.03751
is negative if theta=0.76 (EMA and recommended by Tothfalusi et.al.) and the MOM terms are used, if I calculated right. And this would indicate scABE proven.

Tothfalusi et.al.
Evaluation of Bioequivalence for Highly Variable Drugs with Scaled Average Bioequivalence
Clin. Pharmacokinet. 2009; 48 (11): 725-743

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
141 visitors (0 registered, 141 guests [including 15 identified bots]).
Forum time: 08:41 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5